Talvey
Medication Quick Facts
📋Overview
Talvey is a bispecific T-cell engager that helps the immune system target and eliminate cancer cells. It works by binding to two different proteins at the same time: one found on the surface of the cancer cells and another found on T cells, which are a type of white blood cell.
By linking these two cells together, the medication allows the immune system to directly attack the cancer. This action helps the body's natural defenses identify and destroy cells that might otherwise go undetected.
Educational information only
This content is provided for general health education and awareness and is based on publicly available medical information. It is not intended to replace professional medical advice, diagnosis, or treatment, and should not be used to make healthcare decisions. Always seek the guidance of a qualified healthcare professional regarding any medical condition, medication, supplement, or procedure.
Multiple Myeloma
Talvey is used to treat adults with multiple myeloma, a cancer that affects plasma cells in the bone marrow. It is specifically indicated for patients with relapsed or refractory disease.
- Relapsed means the cancer has come back after a previous treatment was successful.
- Refractory means the cancer did not respond to treatment or stopped responding to the most recent therapy.
Prior Treatment History
Because Talvey is often used when other options have been exhausted, it is only approved for patients who have already received at least four prior lines of therapy. These previous treatments must have included specific classes of medications, such as:
- Proteasome inhibitors.
- Immunomodulatory agents.
- Anti-CD38 monoclonal antibodies.
Mechanism of Action
Talvey is a type of immunotherapy known as a bispecific T-cell engager. It is designed to act as a bridge between the body's immune system and cancer cells to help the body fight multiple myeloma.
The medication works by targeting two specific proteins at the same time:
- GPRC5D: A protein found on the surface of multiple myeloma cells.
- CD3: A protein found on the surface of T-cells, which are white blood cells responsible for fighting disease and infection.
By attaching to both of these proteins simultaneously, Talvey brings the T-cells into close physical contact with the myeloma cells. This proximity allows the T-cells to recognize the cancer cells and release substances that destroy them. This process helps the immune system more effectively find and eliminate cancer cells that might otherwise hide from the body's natural defenses.
Common Side Effects
The most frequent side effects associated with Talvey involve changes to the skin, nails, and mouth. These may include:
- Taste changes: Loss of taste or a metallic taste in the mouth.
- Skin reactions: Rash, dry skin, itching, or peeling.
- Nail changes: Brittle, discolored, or painful nails.
- Mouth issues: Dry mouth, mouth sores, or difficulty swallowing.
- General symptoms: Fatigue, weight loss, fever, and muscle or joint pain.
- Digestive issues: Nausea or diarrhea.
Serious Side Effects
Talvey can cause serious or life-threatening reactions. Seek medical help immediately if you experience symptoms of the following:
- Cytokine Release Syndrome (CRS): This is a common but serious reaction. Symptoms include fever, chills, fast heartbeat, low blood pressure, and trouble breathing.
- Neurologic problems: Confusion, disorientation, sleepiness, headaches, or difficulty speaking.
- Infections: Talvey can weaken the immune system, making it easier to get serious or life-threatening infections.
- Low blood cell counts: Decreased levels of white blood cells, red blood cells, or platelets can increase the risk of infection, fatigue, and bleeding.
- Liver problems: Changes in liver function tests may occur, which could indicate liver toxicity.
The side effects listed here are not exhaustive. Individual reactions may vary. For complete safety information, consult official prescribing resources or a healthcare professional.
Boxed Warning: CRS and Neurologic Toxicity
Talvey has a boxed warning for two potentially life-threatening conditions: Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Due to these risks, the medication is only available through a restricted distribution program called the Talvey REMS.
Cytokine Release Syndrome (CRS)
CRS is a serious systemic inflammatory response. Symptoms may include fever, chills, low blood pressure, and difficulty breathing. Monitoring typically occurs in a clinical setting during and after the initial doses.
Neurologic Toxicity
Neurologic side effects can be severe. Symptoms may include confusion, headache, dizziness, tremors, or changes in consciousness. Patients are generally advised to avoid driving or operating heavy machinery for a specific period after starting treatment or following dose increases.
Oral and Skin Toxicities
Talvey can cause significant issues affecting the mouth, skin, and nails. These may include:
- Oral issues: Changes in taste (dysgeusia), dry mouth, and difficulty swallowing. These conditions can lead to significant weight loss.
- Skin and nail reactions: Rashes, skin peeling, and changes to the fingernails or toenails.
Infections and Blood Counts
Treatment may increase the risk of serious or fatal infections. It can also cause cytopenias, which are low levels of white blood cells, red blood cells, or platelets. Regular blood tests are used to monitor for these conditions.
Pregnancy and Reproductive Health
Talvey may cause fetal harm if administered to a pregnant woman. Effective contraception is recommended during treatment and for a specified duration after the last dose.
Administration Method
Talvey is given as a subcutaneous injection, which means it is injected into the layer of fat just under the skin. Common injection sites include the stomach area or the thigh. A healthcare provider will perform the injection in a clinical setting, such as a hospital or infusion center.
Dosing Schedule
Treatment with Talvey usually follows a specific pattern known as a step-up dosing schedule. This process involves receiving smaller doses a few days apart at the start of treatment. This approach helps the body adjust to the medication before moving to the full treatment dose.
Once the initial step-up phase is complete, the medication is typically administered on a regular maintenance schedule. Depending on the treatment plan determined by a doctor, injections may be given once every week or once every two weeks.
Monitoring During Treatment
Because of the potential for certain reactions, patients are often required to stay at the healthcare facility for monitoring for a period of time after receiving the first few doses. This allows medical staff to watch for and manage any immediate side effects.
Missed Doses
It is important to receive every scheduled dose of Talvey. If an appointment is missed, patients should contact their healthcare provider as soon as possible to reschedule. The provider will determine the best way to get back on schedule, which may involve repeating certain steps of the dosing process if too much time has passed between injections.
❗Suspected Overdose
Taking more than the prescribed amount of Talvey can be dangerous. If an overdose is suspected, seek emergency medical care immediately. Call 911 or contact Poison Control at 800-222-1222 for immediate guidance.
Pregnancy
Talvey can cause harm to a fetus if used during pregnancy. Healthcare providers typically perform a pregnancy test before starting treatment to ensure a patient is not pregnant.
Females who are able to become pregnant should use effective birth control (contraception) during treatment and for at least 3 months after the final dose. If a patient becomes pregnant while using this medication, they should notify their healthcare provider immediately.
Breastfeeding
It is not known if Talvey passes into human breast milk. Due to the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 3 months after the last dose.
Patients should discuss their options for infant feeding with their healthcare team before starting this medication.
Available Forms
Talvey is available as a liquid solution for injection. It is administered as a subcutaneous injection, which is an injection given into the tissue just under the skin.
This medication is supplied in vials for use by a healthcare professional.
FDA Approval Status
Talvey (talquetamab-tgvs) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2023. It is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Boxed Warning
The FDA requires a Boxed Warning for Talvey because it can cause serious or life-threatening side effects, including:
- Cytokine Release Syndrome (CRS): A condition where the immune system reacts too strongly to the medication.
- Neurologic Toxicity: This includes Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can cause symptoms like confusion, disorientation, or loss of consciousness.
REMS Program
Because of the risks of CRS and neurologic toxicity, Talvey is only available through a restricted program called the Tecvayli-Talvey Risk Evaluation and Mitigation Strategy (REMS). Healthcare providers who prescribe Talvey and the facilities that dispense it must be specially certified. Patients must also be enrolled in the program and receive a Patient Wallet Card to carry at all times.
Regulatory Monitoring
The FDA continues to evaluate the safety of Talvey through the FDA Adverse Event Reporting System (FAERS). This system tracks potential signals of serious risks or new safety information identified after the drug has been approved for public use.
Based on current clinical data and prescribing information, there are no reported withdrawal symptoms associated with stopping Talvey. This medication is a bispecific antibody used for immunotherapy and does not cause physical dependence or the types of withdrawal effects seen with medications that affect the central nervous system, such as opioids or sedatives.
Although withdrawal is not a concern, you should only stop using Talvey under the direction of your healthcare provider. Discontinuing treatment may allow the underlying multiple myeloma to progress. Your doctor may decide to delay or permanently stop treatment if you experience certain serious side effects, including:
- Cytokine release syndrome (CRS)
- Neurologic problems (ICANS)
- Severe skin reactions
- Serious infections
- Liver toxicity
If your treatment is discontinued, your healthcare team will continue to monitor you for any changes in your condition or lingering side effects from the medication.
Overall User Experience
No experiences shared yet — be the first to share your experience.
Shared experiences are personal and do not replace medical advice.
Share Your Experience with Talvey
Answer each question one at a time. Your full experience is submitted only after the last question. Responses are anonymous.
Effectiveness
How effective was this medication for you?
Not effective at all → Extremely effective
One question at a time · submitted at the end
Found an Error?
Help us keep this information accurate. If you notice any incorrect details, please submit a correction request.